Welcome to the
Our lab devises methods to selectively kill cancer cells by better understanding apoptotic cell death
|
|
Our Bulletin Board
|
Trying to kill senescent cells? It's not impossible after all- In Julie MacDonald's new papers we used BH3 profiling to measure apoptotic priming across a variety of senescent cells and found senescent cells were less primed for death, explaining why these cells were previously thought to be "resistant to apoptosis." Additionally, BH3 profiling identified which senescent cell were dependent on BCL-xL for survival and found a strong correlation with BCL-xL dependence and sensitivity to the BH3 mimetic drug Navitoclax (ABT-263). However, senescent cells are not universally dependent on BCL-xL, and using changes in the senescent proteome, we identified new senolytic drug combinations to better eliminate senescent cells in cases where ABT-263 alone isn't enough.
Read more here: https://rdcu.be/d5rb3 and https://rdcu.be/d5rjW 
|
|
|
Jason Wu, Cole Turner, Dr. Anthony Letai, Jeremy Ryan, Shaili Soni, and Maria Davern showing their Halloween spirit at a staff Halloween gathering.
|
Will Sanborn and Letai Lab's Jeremy Ryan out on the Jimmy Fun Walk course on October 6th taking on the full 26.2 mile Boston Marathon route. The Jimmy Fund Walk helps raise funds for patient care and research.
Dana-Farber video of how BCL-2 research helps patients at Dana-Farber.
Dana-Farber’s Momentum of Discovery – Featuring Drs. Anthony G. Letai and Jacqueline S. Garcia.
|
Acquired resistance targeted functionally in AML
|
|
Happy Holidays from the Letai to you. Pictures from our annual Holiday Party.
|
|
|
Salma Parvin has just published a great paper on CLL https://shorturl.at/knqK0. Identifiable subsets of CLL (incl IgHV unmutated) are less primed for apoptosis, less mature, and - importantly!- sensitive to FLT3 inhibition! Please check it out.
|
|
|
|
|